BillionToOne, Inc. (BLLN)
Nasdaq: BLLN · Services-Medical Laboratories · Menlo Park, CA · filing with the SEC since 2025
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 11, 2026 | · | · |
| Revenue | 305,112.0 | 152,582.0 | 71,729.0 |
| Cost of revenue | 96,654.0 | 71,667.0 | 54,421.0 |
| Gross profit | 208,458.0 | 80,915.0 | 17,308.0 |
| Research and development | 49,384.0 | 36,596.0 | 22,414.0 |
| Selling, general and administrative | 143,051.0 | 91,465.0 | 64,389.0 |
| Total operating expenses | 192,435.0 | 128,061.0 | 86,803.0 |
| Operating income | 16,023.0 | -47,146.0 | -69,495.0 |
| Interest expense | 95.0 | 2,386.0 | 3,272.0 |
| Interest and investment income | 7,750.0 | 5,819.0 | 3,456.0 |
| Other income (expense), net | -7,410.0 | -1,145.0 | -442.0 |
| Total non-operating income (expense) | -8,264.0 | 5,605.0 | -13,179.0 |
| Income before income taxes | 7,759.0 | -41,541.0 | -82,674.0 |
| Income tax expense | 305.0 | 29.0 | 9.0 |
| Net income | 7,454.0 | -41,570.0 | -82,683.0 |
| Net income to common shareholders | 2,919.0 | -41,570.0 | -82,683.0 |
| Earnings per share, basic | 0.18 | -4.12 | -8.45 |
| Earnings per share, diluted | 0.14 | -4.12 | -8.45 |
| Weighted average shares, basic | 15,875,091 | 10,079,925 | 9,782,770 |
| Weighted average shares, diluted | 21,230,752 | 10,079,925 | 9,782,770 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding